Mark R. Bamforth
Mark joined Ampersand as an Operating Partner in 2018 and transitioned to an Executive Advisor in 2023. Mark is the Founder of two former Ampersand portfolio companies: Brammer Bio, a leading cell and gene therapy CDMO, and Arranta Bio, a leading CDMO for mRNA. Mark served as the CEO of Brammer until the sale of the company to Thermo Fisher Scientific in 2019. Mark also served as the Executive Chair of the Board and CEO at Arranta Bio and a Board member of TriPharm, a former Ampersand portfolio company. Previously, Mark founded Gallus BioPharmaceuticals, a premier CDMO delivering clinical and commercial mammalian-based biopharmaceuticals, which was sold to DPx Holdings B.V. (Patheon) in September 2014. Prior to Gallus, Mark spent 22 years in the UK and USA, running global operations and a pharmaceutical CMO business for Genzyme Corp. His work at Genzyme included supporting cell therapy and gene therapy clinical trials resulting in the first FDA approval of a cell therapy product. He currently serves on the Boards of Inceptor Bio, CONTINUUS Pharmaceuticals, EnteroBiotix, and Pneumagen Limited. Mark is also a founding trustee of the Saltire Foundation. He holds a B.S. in Chemical Engineering from Strathclyde University and a M.B.A. from Henley Management College.